Previous 10 | Next 10 |
Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Canada NewsWire VANCOUVER, Dec. 7, 2019 - New analyses of Phase 3 data highlighting momelotinib's meaningful anemia benefit...
Amedisys (NASDAQ: AMED ) initiated with Market Perform rating and $170 (3% upside) price target at BMO. More news on: Amedisys, Inc., Athenex, Inc., Gossamer Bio, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
These Penny Stocks Are Running Strong; Are They A Buy Or Sell Right Now? There are certain sectors in the stock market that are more favored than others. That’s simply due to the track record of the companies as well as the big swings some sector stocks see. Technology & biotech are...
Are Any Of These Penny Stocks On Your Watch List Right Now? When it comes to penny stocks to watch , timing can play a role in your strategy. Certain corporate events, disclosure filings, and even industry news can act as significant catalysts for stocks to break out. But then again, some com...
Sierra Oncology Announces Investor Event to Discuss Momelotinib Data Being Reported at ASH Canada NewsWire VANCOUVER, Dec. 2, 2019 - Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 7:00 am ET on December 8 th - - Data highlighting decrease...
3 Penny Stocks To Watch As 2019 Comes To End Some penny stocks can often hit new highs seemingly out of nowhere. But it’s important to note that the tell-tale signs could already be in play before the big move even begins. When it comes to identifying some of the top penny stocks to...
VANCOUVER , Nov. 26, 2019 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treat...
Sierra Oncology (NASDAQ: SRRA ) has launched the MOMENTUM clinical trial for patients with myelofibrosis. More news on: Sierra Oncology, Inc., Healthcare stocks news, Stocks on the move, Read more ...
- MOMENTUM trial designed to confirm the unique benefits of momelotinib on all three hallmarks of myelofibrosis: symptoms, anemia and enlarged spleen - - Targeting enrollment of 180 symptomatic and anemic patients previously treated with a JAK inhibitor – - Top-line data anticipated i...
Sierra Oncology to Present at the Jefferies 2019 London Healthcare Conference Canada NewsWire VANCOUVER, Nov. 14, 2019 - "Building Momentum for Patients with Myelofibrosis" scheduled for 6:00 p.m. GMT on November 20, 2019 - VANCOUVER , Nov. 14, 2019 /CNW/ - Sierra O...
News, Short Squeeze, Breakout and More Instantly...
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEO John Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading en...
– Submission seeks approval of momelotinib for the treatment of myelofibrosis – Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submi...